Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Gout Detected from a Simple Blood Sample

By Labmedica International staff writers
Posted on 31 Oct 2013
Print article
An in vitro diagnostic test, which detects active Gout disease from samples of whole blood, has been launched in Europe.

The CE marked GoutiFind test takes a new approach to Gout diagnosis. Based on a key scientific discovery of how our immune system reacts to uric acid crystal deposition in joints, the GoutiFind test measures the cellular immune response to the deposits. No special clinical setting is required for the GoutiFind test. A fresh blood sample drawn in a physician’s office or clinical laboratory is all that is required for the GoutiFind test.

The GoutiFind test is offered throughout the EU as a diagnostic service by Boulder Diagnostics (Mellrichstadt, Germany) clinical diagnostic service laboratory. The GoutiFind test detects active Gout disease without employing the unreliable determination of the uric acid level. It therefore provides a noninvasive reliable diagnosis of Gout disease.

The GoutiFind test can replace the invasive joint puncture method for Gout detection and thus make reliable Gout diagnosis available to a much broader range of medical institutions and physician practices. The test is based on measuring the cellular immune response to a specific challenge with a Gout stimulus.

"The GoutiFind test simplifies and makes Gout diagnosis more broadly available," commented Dr. Wolfgang Pieken, CEO of Boulder Diagnostics Inc., and added, "the GoutiFind test is the second product from our technology platform that queries the trained immunity for active disease."

"At our clinical laboratory in Mellrichstadt, Germany, we now accept whole blood samples for Gout detection by the GoutiFind method," stated Dr. Anton Waldherr, laboratory physician of Boulder Diagnostics Europe GmbH.

Related Links:

Boulder Diagnostics



Print article

Channels

Clinical Chemistry

view channel
Image: Dried blood spots are used to screen newborns for a number of rare inherited conditions. A new dried blood spot screening test has been developed for Niemann-Pick type C, a rare neurodegenerative condition that usually is not diagnosed until after damage to brain cells has begun (Photo courtesy of Washington University School of Medicine).

Newborn Screening Test Developed For Deadly Neurological Disorder

A newborn screening test has been introduced that identifies infants with Niemann-Pick disease type C, an often fatal condition in which cholesterol builds up and eventually destroys brain cells.... Read more

Genetic Tests

view channel
Image: The BioMek FXP automation workstation (Photo courtesy of Beckman Coulter).

Innovative Gene Testing Technology Finds Cancer Risks

A new method has been developed for identifying mutations and prioritizing variants in breast and ovarian cancer genes, which will not only reduce the number of possible variants for doctors to investigate,... Read more

Pathology

view channel
Image: A photomicrograph of an abnormal Pap smear showing changes consistent with Human Papilloma Virus (HPV) and Mild Dysplasia. Note the irregular perinuclear cytoplasmic clearing, which is the key characteristic of identifying HPV visually on a Pap smear (Photo courtesy of Dr. Cynthia D Booth, MD).

Combining Two Diagnostic Tests Drastically Reduces Cancer Miss Rates

The Papanicolaou (Pap) test is recommended for women between 21 and 65 years old as a screening test for cervical cancer. Women 30 and older who are negative on co-testing may wait as long as five years... Read more

Lab Tech.

view channel
Image: Candida albicans growing on Sabouraud agar (Photo courtesy of Dr. William Kaplan / CDC).

Chemical Sensor Rapidly Detects Fungal Infections

An elevated concentration of D-arabitol, a simple sugar alcohol, in urine, especially compared to that of L-arabitol or creatinine, is indicative of a fungal infection, which can become deadly.... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.